1085842-51-8

Basic information

• Product Name: Trans-(1S,2S)-Methyl 3-aMinocyclopentanecarboxylate hydrochlorid
• Synonyms: Trans-(1S,2S)-Methyl 3-aMinocyclopentanecarboxylate hydrochlorid;methyl (1S,3S)-3-aminocyclopentane-1-carboxylate hydrochloride;(1S,3S)-Methyl 3-aminocyclopentanecarboxylate hydrochloride;(1S,3S)-METHYL 3-AMINOCYCLOPENTANECARBOXYLATE HCL
• CAS NO: 1085842-51-8
• Molecular Formula: C₇H₁₃NO₂*ClH
• Molecular Weight: 179.65
• Mol File: 1085842-51-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Trans-(1S,2S)-Methyl 3-aMinocyclopentanecarboxylate hydrochlorid(CAS DataBase Reference)
• NIST Chemistry Reference: Trans-(1S,2S)-Methyl 3-aMinocyclopentanecarboxylate hydrochlorid(1085842-51-8)
• EPA Substance Registry System: Trans-(1S,2S)-Methyl 3-aMinocyclopentanecarboxylate hydrochlorid(1085842-51-8)

Safety Data

• Hazardous Substances Data: 1085842-51-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Trans-(1S,2S)-Methyl 3-amino cyclopentanecarboxylate hydrochloride is used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its unique stereochemistry and hydrochloride salt form make it a valuable component in the development of new drugs.
Used in Neurological Disorders Treatment:
Trans-(1S,2S)-Methyl 3-amino cyclopentanecarboxylate hydrochloride is used as a therapeutic agent for the treatment of neurological disorders. Its potential in this area is attributed to its ability to modulate specific biological pathways and target receptors involved in the pathophysiology of these conditions.
Used in Infectious Diseases Treatment:
Trans-(1S,2S)-Methyl 3-amino cyclopentanecarboxylate hydrochloride is also used as a therapeutic agent in the treatment of infectious diseases. Its potential in this field is due to its ability to target and inhibit the growth of various pathogens, thereby providing a potential treatment option for patients suffering from these conditions.

Upstream product

• 75-36-5 acetyl chloride 
• 329910-39-6 (1S,3S)-1-(tert-butoxycarbonylamino)cyclopentane-3-carboxylic acid methyl ester 

Downstream Products

• 1008770-32-8 (1s,3R)-3-(4-(5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl)benzylamino)cyclopentanecarboxylic acid methyl ester 
• 329910-39-6 (1S,3S)-1-(tert-butoxycarbonylamino)cyclopentane-3-carboxylic acid methyl ester 

Relevant articles and documents

Pyrrolopyrazinyl Urea Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, wherein the variables R1, R2, R3, R4, and R5 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.